KESTRA MED TECHNOLOGIES LTD Stock Price, News & Analysis

Kestra Medical Technologies (NASDAQ:KMTS), a wearable medical device company, reported strong Q4 and FY2025 results. Q4 revenue reached $17.2 million, up 71% year-over-year, while FY25 revenue hit $59.8 million, a 115% increase from FY24. The company's ASSURE® cardiac recovery system saw 13,193 prescriptions in FY25, up 72% from the previous year.

Gross margins significantly improved to 44.3% in Q4 FY25 from 13.9% in the prior year, and 40.5% for FY25 compared to 1.3% in FY24. Despite growth, the company reported a GAAP net loss of $51.1 million in Q4 and $113.8 million for FY25. Looking ahead, Kestra projects FY26 revenue of $85 million, representing 42% growth.

[ "Revenue grew 115% year-over-year to $59.8 million in FY25", "Significant gross margin expansion to 40.5% in FY25 from 1.3% in FY24", "Strong prescription growth with 13,193 ASSURE® system prescriptions in FY25, up 72%", "Robust cash position of $237.6 million as of April 30, 2025", "Projected 42% revenue growth for FY26 with $85 million guidance" ]

Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Tuesday, July 15, 2025. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can access both the live and archived webcast through the "Events" section of Kestra's investor relations website, with registration recommended at least 10 minutes before the call.

Archimedes Vascular, a pre-clinical stage medical device company, has secured $2.2 million in Series A financing led by Sherpa Healthcare Partners. The company is developing an implant for treating severe hypertension and has appointed Raymond W. Cohen as Chairman of its Board of Directors. Cohen brings significant industry experience, having previously served as CEO of Axonics, which ranked No. 1 on Deloitte Technology Fast 500 and Financial Times fastest-growing companies lists in 2021-2022, before being acquired by Boston Scientific. Cohen also served as Chairman of SoniVie, which was sold to Boston Scientific in March 2025. The funding will support pre-clinical work as Archimedes seeks FDA clearance for initial human clinical studies.

Kestra Medical Technologies (NASDAQ: KMTS), a wearable medical device and digital healthcare company, has announced its inclusion in the Russell 3000® Index and Russell 2000® Index, effective June 27, 2025. This milestone follows the company's IPO in March 2025 and is part of Russell's annual reconstitution process that captures the 4,000 largest U.S. stocks by market capitalization. The inclusion signifies Kestra's growing market presence, with approximately $10.6 trillion in assets benchmarked against Russell U.S. indexes. CEO Brian Webster emphasized the company's commitment to protecting patients at risk of sudden cardiac arrest while creating long-term shareholder value.

Kestra Medical Technologies (NASDAQ: KMTS) has appointed Conor Hanley as an independent director to its board, effective June 4, 2025. Hanley brings significant expertise in medical technology and cardiac care as the current CEO of FIRE1, a connected medical device company focused on heart failure solutions. His extensive experience includes senior management roles at ResMed, where he led the cardiology business unit and chronic disease management solutions globally. Hanley was also co-founder and CEO of BiancaMed, later acquired by ResMed. He holds a PhD in chemical engineering from the University of Pennsylvania and an MBA from INSEAD. The appointment aims to support Kestra's growth and expansion of its ASSURE® system in the wearable cardioverter defibrillator market.

Kestra Medical Technologies (Nasdaq: KMTS), a company specializing in wearable medical devices and digital healthcare, has announced its participation in two major upcoming investor conferences.

The company will present at the following events:

• BofA Securities 2025 Health Care Conference on May 14 at 6:40 p.m. ET
• Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 11 at 8:00 a.m. ET

Investors and interested parties can access live webcasts and replays of both presentations through Kestra Medical Technologies' investor relations website.

Kestra Medical Technologies presented new real-world data for their ASSURE Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025 in San Diego. The study focused on outcomes in a community-based setting using an advanced practice provider (APP)-driven protocol.

Key findings demonstrate:

• High patient compliance with 23.3 hours median daily wear time
• Consistent usage beyond 90 days
• 4% of patients showed ventricular arrhythmias detection
• Successful implementation of APP-driven care model
• Effective continuity of care through ICD placement or hospitalization when needed

The study validates ASSURE's effectiveness in protecting patients from sudden cardiac arrest through both clinical performance and patient engagement. The results highlight the success of structured, team-based approaches in expanding access to cardiac care within community settings.

Kestra Medical Technologies (Nasdaq: KMTS) announced its participation in Heart Rhythm 2025, the annual Heart Rhythm Society meeting, scheduled for April 24-27 at the San Diego Convention Center. This marks the company's first major industry showcase following its recent IPO.

The company will showcase its ASSURE® system, a wearable medical device that combines defibrillation therapy with diagnostic and patient support capabilities. The exhibition will feature an immersive in-booth experience demonstrating the system's role in protecting patients at risk of sudden cardiac arrest.

During the event, Kestra will present new real-world clinical data about the ASSURE system's impact and continue its sponsorship of the Women in EP Luncheon for the fourth consecutive year.

Kestra Medical Technologies (NASDAQ: KMTS) reported strong Q3 FY25 financial results with revenue of $15.1 million, up 82% year-over-year. The company achieved a significant improvement in gross margin to 43.4% from 10.6% in the prior year period.

Key highlights include 3,459 prescriptions written for the ASSURE® system, representing a 51% increase. The company successfully completed its IPO in March 2025, raising $205.2 million in net proceeds. Kestra expanded its insurance coverage network, now reaching over 285 million health plan members in the United States.

For fiscal year 2025 ending April 30, Kestra projects revenue between $58.0-58.5 million, indicating approximately 109-110% growth compared to FY24. However, the company reported a GAAP net loss of $21.8 million and an adjusted EBITDA loss of $16.3 million for Q3 FY25.